Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Isolated mutant protein of fibroblast growth factor 18 and pharmaceutical composition comprising the same

a technology of fibroblast growth factor and mutant protein, which is applied in the field of mutant protein, can solve the problems that no such factors have been discovered, and achieve the effect of regulating physiological activity

Inactive Publication Date: 2011-02-22
NAT INST OF ADVANCED IND SCI & TECH
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0031]The novel mutant FGF18 proteins according to the present invention have different receptor specificities from the reaction specificity that naturally secreted FGF18 has for its receptor. This makes it becomes possible to regulate a physiological activity of FGF18 positively or negatively.

Problems solved by technology

However, no such factors have been discovered yet.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Isolated mutant protein of fibroblast growth factor 18 and pharmaceutical composition comprising the same
  • Isolated mutant protein of fibroblast growth factor 18 and pharmaceutical composition comprising the same
  • Isolated mutant protein of fibroblast growth factor 18 and pharmaceutical composition comprising the same

Examples

Experimental program
Comparison scheme
Effect test

examples

[0076]Hereinafter, the present invention will be described in great detail with reference to the following examples, to which the present invention is by no means limited.

(1) Construction of Plasmids

Construction of Plasmids Carrying cDNAs Encoding Mouse Mutant FGF18 Proteins

[0077]cDNA molecules encoding mouse mutant FGF18 proteins can be produced as follows.

[0078]As the material for the production, a piece of skin was removed from a 7-week-old male C3H / HeN mouse (Japan SLC, Hamamatsu, Japan), and RNA was extracted from the skin. One microgram of the mouse RNA was added with 120 ng of random hexanucleotide DNA (GIBCO BRL, Tokyo, Japan). By using 200 units of M-HLV reverse transcriptase (GIBCO BRL, Tokyo, Japan), a cDNA mixture was prepared.

[0079]From the cDNA mixture, cDNA encoding mouse full-length FGF18 was amplified by PCR. The sequences of the primers used in the PCR are as follows.

[0080]

Sense primer:(SEQ ID NO: 51)5′-ATGTATTCAGCGCCCTCCGCCTGCACTTGCCTGT-3′Anti-sense primer:(SEQ ID...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
humidityaaaaaaaaaa
humidityaaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

Disclosed is a mutant protein having an altered fibroblast growth factor receptor specificity, which is produced by deleting one or more amino acid residues from the N-terminus of the amino acid sequence of naturally secreted fibroblast growth factor 18. The protein mutant can be used in a pharmaceutical composition for regulating hair regeneration or growth or a pharmaceutical composition for regulating bone or cartilage formation.

Description

FIELD OF THE INVENTION[0001]The present invention relates to mutant growth factor proteins having altered receptor specificities, which are produced by deleting appropriate numbers of amino acid residues from the N-terminus of fibroblast growth factor 18 (FGF18) protein. The present invention also relates to a pharmaceutical composition comprising the mutant growth factor protein as an active ingredient.BACKGROUND ART[0002]Heretofore, it is known that the fibroblast growth factor (FGF) ligand family comprises 22 members in humans and mice, and that each of these members has an inherent reaction specificity for one or more of seven FGF receptor (FGFR) subclasses, namely FGFR1c, FGFR1b, FGFR2c, FGFR2b, FGFR3c, FGFR3b and FGFR4. It is generally believed that the diversity of the physiological functions of FGF ligands is often explainable in terms of the combinations of various ligands and various receptors. On the other hand, few cases are known in which the inherent receptor specifici...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K38/18C07K14/50
CPCA61K8/64A61Q7/00C07K14/50A61K38/00A61P17/14A61P19/08A61P25/00A61P25/28A61P43/00
Inventor IMAMURA, TORUTSUJINO, NOZOMISUZUKI, MASASHIASADA, MASAHIRO
Owner NAT INST OF ADVANCED IND SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com